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Purpose: Cancer genetics has emerged as a critical specialty within the field of genetic 
counseling. Advancements in research are constantly uncovering new insights into the 
genetics of cancer and inherited cancer syndromes. It is crucial that genetic counselors 
and the institutions in which they work are in sync with these advancements. Currently, 
multiplex or multi-gene cancer testing is rapidly being adapted into the cancer genetic 
counseling setting. The ‘hot topic’ of an increased likelihood of receiving variant results 
following such testing has been explored in depth in the literature. However, research 
surrounding genetic counseling practices and the reclassification of VUS results is 
lacking. No consensus guidelines addressing variant reclassification yet exist. This study 
aimed to identify current practices of genetic counselors with regard to variant 
reclassification, and to explore whether genetic counselors feel they need official 
guidelines relating to the reclassification of variant results. 
Method: An online survey distributed through the National Society of Genetic 
Counselors and the Cancer Special Interest Group (SIG) was utilized in this research 
study. Statistical Analysis System (SAS) 9.4 was employed for quantitative data and 
statistical analysis while qualitative data was coded and analyzed for major themes using 
grounded theory methods.  
Results: We determined that cancer genetic counselors are handling the reclassification 
of VUS results in a unified manner. Common themes across almost 200 respondents 
demonstrated that they approach benign or deleterious reclassification in a similar 
 vi 
fashion. 95% of respondents (n = 209) discuss variant reclassification with their patients 
upon receiving a VUS result. Similarly, 95% of respondents (n = 209) will sometimes or 
always make a plan to communicate VUS reclassification results should they arise in the 
future. The overwhelming majority (97%) of respondents (n = 183) indicated that the 
protocol for re-contacting patients with a VUS reclassification would not be different 
from what they had used in the past for single-gene analysis. Varying opinions existed on 
whether practice guidelines relating to VUS reclassification are necessary. The majority, 
62% of respondents (n = 178), agreed or strongly agreed that there was a need for 
guidelines relating to variant reclassification. Those who disagreed expressed concerns 
surrounding liability issues and the feasibility of implementing recommendations across 
different institutions.  
Conclusions: Findings from this study indicate that most genetic counselors are utilizing 
unified practices when handling the reclassification of variant results. Additionally, a 
proportion of genetic counselors felt that guidance or recommendations for certain areas 
relating to variant reclassification are necessary. While future research is needed to 
explore more in-depth the issues and opinions identified in this research project, another 
possible approach is for the NSGC Cancer SIG to address this topic at their earliest 
opportunity, given the coming wave of VUS reclassifications from multiple collaborative 
efforts to more urgently reclassify VUS results.  
 Keywords: Cancer genetics, genetic testing, multi-gene panels, multiplex genetic 
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Chapter 1. Background 
The basis of an inherited susceptibility to cancer is complex. Mutations in specific genes 
can increase an individual’s risk for developing cancer (Domchek, Bradbury, Garber, 
Offit, & Robson, 2013). Identifying mutations in these cancer predisposition genes is a 
valuable clinical tool, as it identifies which individuals are at a particularly high risk of 
developing cancer. Traditionally, it has been common practice to analyze single genes for 
mutations. The genes being analyzed are those that are the most likely to carry mutations, 
dependent on one’s personal and family history (Domchek et al., 2013; Mauer, Pirzadeh-
Miller, Robinson, & Euhus, 2014). If no mutation is identified, further single gene tests 
may then be carried out (Domchek et al., 2013; Mauer et al., 2014). An example of this is 
the traditional manner in which testing has been conducted to uncover a genetic cause for 
Hereditary Breast and Ovarian Cancer (HBOC) Syndrome. Mutations in BRCA1 and 
BRCA2 increase the risk for breast and ovarian cancer and are the most common genes 
associated with HBOC Syndrome (Hall et al., 1990; Hilbers, Vreeswijk, van Asperen, & 
Devilee, 2013; Wooster et al., 1995). HBOC syndrome was originally linked to an 
autosomal dominant trait in the early 70’s and it was in the years following that BRCA1 
and BRCA2 were identified (Lynch, Snyder, & Casey, 2013). Since their discovery in the 
mid 1990’s, these two genes have dominated much of research and thus have led to the 
recommendation of specific surgical and management interventions when a mutation is 
identified (Lee & Ang, 2014; Rainville & Rana, 2014). National recommendations 
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 outlining surveillance options, prophylactic surgical measures and chemoprevention for 
BRCA1 or BRCA2 mutation carriers exist (Pruthi, Gostout, & Lindor, 2010; Robson & 
Offit, 2007).  
Since the identification of BRCA1 and BRCA2, multiple other genes involved in 
the same DNA repair pathway have been uncovered (Lynch et al., 2013; Rainville & 
Rana, 2014). Although BRCA1 and BRCA2 remain the main players and account for the 
majority of HBOC syndrome cases, other genes are now known to modify an individual’s 
risk. Some examples include genes such as TP53, PTEN, NBN and STKII (Hilbers et al., 
2013; Kobayashi, Ohno, Sasaki, & Matsuura, 2013; Lynch et al., 2013; Rainville & Rana, 
2014).  In addition, a more recent discovery is the PALB2 gene, partner and localizer of 
BRCA2. PALB2 is considered a ‘moderate risk’ susceptibility gene; if a deleterious 
mutation is identified the susceptibility to breast and pancreatic cancer increases 
(Hofstatter et al., 2011; Rainville & Rana, 2014; Tischkowitz et al., 2009). Some of the 
cancer susceptibility genes that can, when mutated, increase an individual’s risk for either 
breast and/or ovarian cancer may in fact be associated with other cancer syndromes and 
not HBOC syndrome. For example, deleterious changes in the mismatch repair genes 
associated with Lynch Syndrome are known to increase the risk for the development of 
ovarian cancer. Despite all these advances there is undoubtedly still more to uncover and 
learn about gene changes that can increase an individual’s risk to certain types of cancer.  
Previously, if no mutations were identified in BRCA1 and BRCA2, it was deemed 
appropriate in specific high-risk patients to carry out serial testing to investigate other 
susceptibility genes. This manner of serial genetic testing can be both time consuming 
and expensive (Domchek et al., 2013). Some may argue that multiplex genetic testing is 
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even less economical. A study conducted by Yorczyk et al. (2014) averaged the dollar 
cost of multiplex genetic testing per person from nine different laboratories and found 
that offering multiplex genetic testing as a first tier approach was 21% more expensive 
than conducting serial genetic testing. The panel test offered to patients as a first tier 
option was the Myriad MyRisk panel that included 25 different genes. Despite this 
increase in cost, authors of the study argued that multiplex genetic testing is cost effective 
due to the higher detection rate and the elimination of multiple follow up clinic visits 
should serial genetic testing be conducted. 
In contrast to how clinical genetic testing has occurred in the past, the 
improvement of sequencing techniques and the advent of next-generation sequencing 
(NGS) technology has allowed for the simultaneous analysis of multiple genes (Domchek 
et al., 2013; Fecteau, Vogel, Hanson, & Morrill-Cornelius, 2014; Mauer et al., 2014; 
Walsh et al., 2010; Wolfe Schneider et al., 2014). Genes included on panels are 
laboratory specific, but it appears there is a general concurrence about which genes 
should be included (Hiraki, Rinella, Schnabel, Oratz, & Ostrer, 2014; Mauer et al., 2014). 
NGS is currently the sequencing method of choice for analyzing multiple genes at the 
same time. It appears that this strategy of testing multiple genes at once is becoming the 
preference for many health professionals (Hiraki et al., 2014; LaDuca et al., 2014). 
Importantly, the cost of multiplex genetic testing is not vastly greater than single gene 
analysis (Domchek et al., 2013; Hilbers et al., 2013; Hiraki et al., 2014). Additionally, 
multiplex genetic testing allows for testing in a timely manner (LaDuca et al., 2014). 
High throughput NGS has allowed for much more time effective sequencing compared to 
single gene analysis using Sanger sequencing (LaDuca et al., 2014; Walsh et al., 2010). 
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Testing laboratories are now advertising a 2-4 week turn-around-time (TAT) for many of 
their panels. 
Furthermore, the use of multiplex genetic testing has allowed for individuals to be 
tested for genes they may not have previously been tested for due to cost, patient fatigue 
or they were considered not consistent with their personal and/or family history (LaDuca 
et al., 2014; Meldrum, Doyle, & Tothill, 2011). As a result, many individuals have 
received a genetic diagnosis that may not have been detected through single gene 
analysis. Yorczyk et al. (2014) found that when offering a single tiered approach 
(beginning with a multiplex cancer panel) the mutation detection rate increased from 
3.8% to 6.7% compared to offering a panel reflexively. In their study group of 105 
individuals, four mutations would not have been identified if single gene analysis were 
conducted. This advanced ability has aided the implementation of a more widespread 
analysis and personalized testing approach (Hiraki et al., 2014; Walsh et al., 2010). The 
clinical implication of being able to rapidly test many genes at once is permeating most 
subspecialties of genetic counseling, including pediatrics, cardiology, prenatal and other 
areas (LaDuca et al., 2014). A specific example of NGS panels outside the cancer realm 
that are becoming widely used includes panels for issues related to intellectual disability 
(Mauer et al., 2014; Walsh et al., 2010).  
The integration of NGS panels does, however, bring with it novel challenges such 
as the increased likelihood of finding an ambiguous result, referred to as a variant of 
uncertain significance or VUS (Domchek et al., 2013; Hilbers et al., 2013; Hiraki et al., 
2014; Walsh et al., 2010; Wolfe Schneider et al., 2014). A VUS is a change in sequence 
for which the implication on gene function is uncertain. Therefore, risk assessment and 
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management options cannot be based on the test result but rather must default to personal 
and family history (Hilbers et al., 2013). For genetic counselors, old practices and 
guidelines are not sufficient to deal with the complexities of multiplex genetic testing and 
the results that come with them (LaDuca et al., 2014). Advances in technology have 
highlighted the need for the establishment of guidelines in clinical practice. 
Molecular laboratories developing cancer gene panels and carrying out testing are 
continuously detecting unique, novel sequence variants (Richards et al., 2008). These 
variants are typically classified within a spectrum with the American College of Medical 
Genetics and Genomics (ACMG) defining different categories of sequence variation 
(Richards et al., 2008; Richards et al., 2015). ACMG along with the Association for 
Molecular Pathology and College of American Pathologists recently recommended the 
use of a 5-tier standard terminology system (Richards et al., 2015) These categories 
include the following: (1) benign; (2) likely benign; (3) uncertain significance; (4) likely 
pathogenic; and (5) pathogenic (Richards et al., 2015). Additionally, ACMG recommends 
that ‘likely’ be used only for variants for which there is over 90% certainty that the 
variant is either benign or deleterious (Richards et al., 2015). Over time, the chance of 
identifying a VUS significantly decreases, as larger data sets are available and the ability 
to review and interpret variants improves (LaDuca et al., 2014; Mauer et al., 2014). For 
example, Myriad reported that they have reduced the VUS rate in BRCA1 and BRCA2 
from 12.8% to 2.1% over ten years during the testing of hundreds of thousands of 
samples from 2002 to 2013 (Eggington et al., 2013).  
A primary reason that individuals undergo genetic testing is to be able to direct 
their own medical management (Vos et al., 2008). Deleterious mutations specifically 
 6
define patient risk and may be accompanied by guidelines for management and treatment, 
while VUS results may warrant risk assessment and management based more heavily on 
family history (Murray, Cerrato, Bennett, & Jarvik, 2011). The National Society for 
Genetic Counseling (NSGC) recommended that personal and family history and not 
genetic testing results be used in order to determine medical management and 
prophylactic options when an uncertain test result is received (Berliner, Fay, Cummings, 
Burnett, & Tillmanns, 2013).  As it is recommended that only individuals who are 
considered ‘high-risk’ and have a strong family history suggestive of a cancer syndrome 
undergo multiplex genetic testing, it makes sense to base any medical decisions on that 
family history when genetic testing results do not provide a clear answer. 
Misinterpretation or misunderstanding of a VUS result or VUS reclassification by the 
physician or patient may lead to sub-optimal management of that individual. 
Additionally, the National Comprehensive Cancer Network (NCCN) does not 
recommend testing of other family members when a VUS is identified. Reclassification 
of a VUS is therefore also critical information for other family members (Murray et al., 
2011). 
Richter et al. (2013) studied both the recall of VUS results and their 
interpretations. Recall is defined as bringing a fact back into one’s mind while 
interpretation is related to explaining the meaning of information one has been told. In a 
study conducted by Richter et al. (2013), 20% of participants were unable to correctly 
recall a VUS result. Recall of results was incorrect more often in individuals with a VUS 
than in individuals who had a positive or negative result. The situation was similar when 
patients were asked to recall the risk associated with the VUS result. Patients categorized 
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as having a VUS had the highest rate of incorrect risk recall and/or incorrect 
interpretation of their VUS result. However, uptake of surgeries and surveillance was 
similar to the ‘negative’ group of patients and worry associated with the risk of cancer 
was similar to those who had a negative result. Vos et al. (2008) focused primarily on 
how the counselee recalls and interprets a test result of uncertain significance. The 
majority, 67%, was able to recall the VUS as not informative, 29% recalled it as a 
pathogenic result, and 4% recalled a non-pathogenic result. However, with regard to 
interpretation, 79% of participants interpreted a VUS as a predisposition to cancer while 
21% interpreted it as non-informative. An additional study supported this outcome by 
showing that the largest difference between recollecting what counselees were told by 
their genetic counselor and how they interpreted the information was found in the group 
who had a VUS communicated to them (Vos et al., 2011). Therefore, patients are at risk 
of recalling a VUS result incorrectly in addition to misinterpreting the meaning of the 
VUS result. 
In an ever-evolving genetics world, patients are expecting to hear and discuss 
genetic aspects of their disease with their primary care physicians (PCPs) (Houwink et 
al., 2011; Miller et al., 2010) have shown that patients not only show genetic test results 
to their PCP’s, but they seek out their advice about what to do with such results. If the 
healthcare profession wants to maximize the benefit of the advances being made, 
important members of the healthcare team need to be educated properly. As part of their 
study Richter et al. surveyed a small cohort of family physicians (n = 21) regarding VUS 
test results (2013). All physicians participating in the study would send a sibling of an 
individual with a VUS for predictive genetic testing. In addition, half of the participating 
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family physicians who referred patients for genetic testing never mentioned the 
possibility of a VUS result. A multitude of studies have also looked at PCPs’ 
understanding of genetic risk, genetic testing, and appropriate referrals. Research has 
suggested that in order for family physicians and PCPs to remain up to date with the 
quick advances occurring in the genetic field, there is a need for improved strategies to 
educate these important healthcare providers. Inevitably, this education will need to 
include education about VUS results as well as reclassification. 
It is feasible to see how genetic counselors can play a role in aiding the 
understanding of the PCPs regarding VUS results and ensure that patients referred are 
receiving appropriate care and information. However, a bigger healthcare wide 
educational program or educational tools may be required.  It is imperative that a 
referring physician can explain a VUS result correctly to his or her patient. In addition to 
educating PCPs about test results, education about the vital importance of reclassification 
and what it could mean for their patients is also critical. 
Reclassification of VUS results may have important implications for a patient’s 
cancer risk assessment in addition to their management options (Murray et al., 2011). 
VUS reclassification is a convoluted and complicated process (Domchek & Weber, 2008; 
Eggington et al., 2013). Reclassification includes constant monitoring of data in the lab, 
literature review, multidisciplinary discussion, as well as searching of public databases to 
continually survey for potential new variants (Eggington et al., 2013). Today, numerous 
different databases and registries exist that are attempting to delineate the association 
between rare, uncommon sequence variants and phenotypes. The goal of these databases 
and registries is to enable clinicians and medical professionals to assess cancer risk and 
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significance of VUS’s found through multiplex cancer testing. An exemplary example of 
one such database is the Evidence – based Network for the Interpretation of Germline 
Mutant Alleles (ENIGMA). ENIGMA is a large consortium consisting of a 
multidisciplinary, international team (Spurdle et al., 2012). In January 2012, over 100 
research scientists and clinicians were involved in the ENIGMA effort. Beginning in 
2009, ENIGMA aimed to start interpreting variants found in BRCA1 and BRCA2 with the 
hope of utilizing what has been learned to expand their efforts to other cancer 
susceptibility genes, most likely beginning with PALB2 and ATM. Researchers clearly 
understood that the variants being uncovered via genetic testing were individually rare 
and uncommon. Thus, building ENIGMA as an international effort would help allow for 
statistically significant data collection. As stated by the consortium, they want to ‘pool 
resources, exchange methods and data and coordinately develop and apply algorithms for 
the classification of BRCA1 and BRCA2’ (Spurdle et al., 2012). In addition, results are 
communicated to the Breast Cancer Information Core (BIC).  
A separate, more recent endeavor with regards to the classification of variants is 
the Prospective Registry of Multi-Plex Testing (PROMPT). PROMPT is a registry that 
aims to gather data required to comprehend the risks that are associated with VUS results 
following multiplex gene testing ("PROMPT to Detail Breast Cancer Risk," 2014). Four 
significant cancer institutes including the Dana-Farber Cancer Institute, Mayo Clinic, 
Memorial Sloan Kettering Cancer Centre, and Abramson Cancer Centre of The 
University of Pennsylvania have partnered with Ambry Genetics, GeneDx, Myriad 
Genetics, Pathway Genomics, and Quest Diagnostics launch this online registry. The 
patient is made aware of PROMPT via the genetic testing laboratories and it is the 
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patient’s own decision whether she/he wishes to share information or not via an online 
website. It has been stated that the study findings will be made public. The efforts of 
PROMPT will begin with breast cancer but eventually will transcend to other cancer 
syndromes. Finally, new information obtained via PROMPT will be provided directly to 
patients.  
Additional registries such as ClinVar also exist. ClinVar is a free and publically 
accessible database whose aim is to define the relationship between genotype and 
phenotype (Landrum et al., 2014). Family studies that are routinely offered to individuals 
presenting with a variant are a separate but also important manner in which variants can 
become reclassified. Together, the aim of all these endeavors is to enable variant cancer 
genetic testing results to have significance and meaning in the clinical setting.  
In addition to the complex process of reclassification, there remains a significant 
question regarding who is ultimately responsible for notifying the patient if 
reclassification occurs. In previous years, ACMG has released statements that help to 
define the process of informing patients of reclassification. Specifically, they 
recommended that the laboratory re-contact primary care physicians when updated 
information regarding VUS reclassification occurs (Richards et al., 2008). This 
responsibility of the laboratory may be particularly important as sequence variations 
identified may be rare in the population, and it may only be single laboratories who have 
knowledge of them (Richards et al., 2008). Myriad Genetic Laboratories, who have 
reclassified BRCA1 and BRCA2 variants over the years, stated that ‘Amended reports are 
sent weekly to healthcare providers who have patients for whom a VUS reclassification 
affects their report’ (Eggington et al., 2013). However, this protocol may be challenged, 
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as the increasing number of tests being ordered will lead to more VUS results and an 
increasing workload. (Eggington et al., 2013).  
The need to set forth clear guidelines and a working plan of who is responsible for 
re-contacting the patient and primary care physician is necessary.  In addition to the 
laboratory, the clinic ordering testing may benefit from implementing a system whereby 
they can re-contact a patient if their VUS becomes reclassified (Murray et al., 2011). 
Thus, the role of the cancer genetic counselor in communicating the possibility of VUS 
results and their clinical implications becomes a critical responsibility. For genetic 
counselors, a primary role is to ensure that the patient is given full and thorough informed 
consent prior to genetic testing. 
Several researchers argue that a patient must also bear some responsibility for 
future re-contact. Murray et al. (2011) cite several examples of practices that are 
currently in place to address this need. For example, the patient must inform the genetic 
counselor and clinic of a change of address. Others propose the patient re-contact the 
clinic every one to three years for an update on whether their particular VUS has been 
reclassified, while others may send a letter to the patient informing them that updated 
information is available and inviting them to contact the clinic for more information. 
Challenges can arise, as it can take many years for a VUS reclassification to occur. For 
example, questions around who should be informed of a VUS reclassification if the 
patient has passed away may be a difficulty that can be an issue. (Fecteau et al., 2014; 
Murray et al., 2011) Some researchers maintain that it may be advisable to discuss this in 
the session with the patient as the reclassification information could be of importance to 
family members in years to come (Murray et al., 2011).  
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Research regarding genetic counseling and VUS reclassification is lacking. 
Addressing some of the issues with multiplex genetic testing, such as reclassification, 
now before the gap widens even more with the growing use of these panels is crucial 
(Hiraki et al., 2014). A survey of 24 Canadian genetic counselors confirmed that all 
would like to see guidelines relating to reclassification and further work required of the 
genetic counselor (Richter et al., 2013). Also, as Mauer et al. (2011) stated, “Providers 
need to be prepared for an increase in case management time and the associated long-
term follow-up of these VUSs in regards to reclassification” (p. 411).  
As of yet, no practice guidelines have been published to which genetic counselors 
should adhere when dealing with multiplex genetic testing and VUS reclassification. This 
study is intended to uncover current ‘best practices’ and identify areas for which genetic 
counselors feel they need direction is of major benefit to this revolutionary field. It 
therefore brings value to not only genetic counselors but also to their patients. It is 
important to note that this study may have wider reaching implications, as the issue of 
VUS reclassification is not unique or limited to cancer genetics only (Plon et al., 2008). 
 13
Chapter 2: Manuscript 
Variant Reclassification in Cancer Genetic Testing: Are Genetic Counselors Prepared? 
A Review of Current Practices 1 
 
                                                           
1 White N.G., White B., Brooks K., & Radford C. To be submitted to Journal of Genetic Counseling. 
 xiv 
2.1 Abstract 
Purpose: Cancer genetics has emerged as a critical specialty within the field of genetic 
counseling. Advancements in research are constantly uncovering new insights into the 
genetics of cancer and inherited cancer syndromes. It is crucial that genetic counselors 
and the institutions in which they work are in sync with these advancements. Currently, 
multiplex or multi-gene cancer testing is rapidly being adapted into the cancer genetic 
counseling setting. The ‘hot topic’ of an increased likelihood of receiving variant results 
following such testing has been explored in depth in the literature. However, research 
surrounding genetic counseling practices and the reclassification of VUS results is 
lacking. No consensus guidelines addressing variant reclassification yet exist. This study 
aimed to identify current practices of genetic counselors with regard to variant 
reclassification, and to explore whether genetic counselors feel they need official 
guidelines relating to the reclassification of variant results. 
Method: An online survey distributed through the National Society of Genetic 
Counselors and the Cancer Special Interest Group (SIG) was utilized in this research 
study. Statistical Analysis System (SAS) 9.4 was employed for quantitative data and 
statistical analysis while qualitative data was coded and analyzed for major themes using 
grounded theory methods.  
Results: We determined that cancer genetic counselors are handling the reclassification 
of VUS results in a unified manner. Common themes across almost 200 respondents 
demonstrated that they approach benign or deleterious reclassification in a similar 
fashion. 95% of respondents (n = 209) discuss variant reclassification with their patients 
upon receiving a VUS result. Similarly, 95% of respondents (n = 209) will sometimes or 





future. The overwhelming majority (97%) of respondents (n = 183) indicated that the 
protocol for re-contacting patients with a VUS reclassification would not be different 
from what they had used in the past for single-gene analysis. Varying opinions existed on 
whether practice guidelines relating to VUS reclassification are necessary. The majority, 
62% of respondents (n = 178), agreed or strongly agreed that there was a need for 
guidelines relating to variant reclassification. Those who disagreed expressed concerns 
surrounding liability issues and the feasibility of implementing recommendations across 
different institutions.  
Conclusions: Findings from this study indicate that most genetic counselors are utilizing 
unified practices when handling the reclassification of variant results. Additionally, a 
proportion of genetic counselors felt that guidance or recommendations for certain areas 
relating to variant reclassification are necessary. While future research is needed to 
explore more in-depth the issues and opinions identified in this research project, another 
possible approach is for the NSGC Cancer SIG to address this topic at their earliest 
opportunity, given the coming wave of VUS reclassifications from multiple collaborative 
efforts to more urgently reclassify VUS results.  
 Keywords: Cancer genetics, genetic testing, multi-gene panels, multiplex genetic 
testing, variant(s), VUS, reclassification  
2.2 Introduction 
Cancer genetics is an ever-evolving specialty within the field of genetic counseling. The 
advent of next-generation sequencing technologies has allowed for the expansion of 
genetic testing options for those individuals considered to be ‘high-risk’ due to personal 





these improvements to ensure they are capable of providing the best possible care to their 
patients. 
Conventionally, sequential single gene analysis has been the manner in which 
genetic testing has been conducted in the cancer setting (Domchek et al., 2013; Mauer et al., 
2014). Genes that were most likely to carry a mutation based on the personal and family 
history were first analyzed. However, advances in sequencing technologies now enable 
the simultaneous analysis of many genes associated with cancer risk (Domchek et al., 
2013; Fecteau et al., 2014; Mauer et al., 2014; Walsh et al., 2010; Wolfe Schneider et al., 
2014). Multiplex genetic testing using next-generation sequencing (NGS) is becoming 
increasingly popular and it appears to be the preference for many healthcare professionals 
(Hiraki et al., 2014; LaDuca et al., 2014). However, analyzing multiple genes 
concurrently brings with it unique and novel challenges. The likelihood that a variant of 
uncertain significance (VUS) will be identified is increased (Domchek et al., 2013; 
Hilbers et al., 2013; Wolfe Schneider et al., 2014). A VUS is a change in sequence for 
which the implication on gene function is unknown. 
 The American College of Medical Genetics and Genomics (ACMG) recently 
defined five different categories of sequence variation (1) benign; (2) likely benign; (3) 
uncertain significance; (4) likely pathogenic; and (5) pathogenic (Richards et al., 2015). 
With the accumulation of larger data sets the VUS rate associated with multiplex genetic 
testing will decrease and in turn VUS reclassification will increase (LaDuca et al., 2014; 
Mauer et al., 2014). The reclassification of VUS results conceivably could have 
significant implications for a patient; the reclassification could alter the patient’s own 





Reclassification may also provide family members with the ability to obtain meaningful 
genetic test results, as NCCN guidelines do not recommend testing of relatives when a 
VUS is identified (Murray et al., 2011).  
As VUS reclassification becomes increasingly common, new practice guidelines 
will perhaps be needed, to specifically address who is responsible for notifying the 
patient (LaDuca et al., 2014).Previously, ACMG has recommended that  laboratories re-
contact primary care physicians when updated information regarding VUS 
reclassification occurs (Richards et al., 2008). Myriad Genetic Laboratories, state that 
‘Amended reports are sent weekly to healthcare providers who have patients for whom a 
variant reclassification affects their report’ (Eggington et al., 2013). In fact, we note that 
these reclassification reports from this company are being sent directly to genetic 
counselors (and presumably other ordering providers) rather than to patients or 
physicians not listed as ordering providers (Personal communication, P. Walker, April, 
2015). As reclassification efforts increase and the workload grows, current practices may 
be difficult to maintain (Eggington et al., 2013).  
Research into genetic counseling and VUS reclassification is lacking. Addressing 
some of the issues associated with multiplex cancer genetic testing is crucial, as variant 
reclassification will continue to occur, presumably at an increasing rate (Hiraki et al., 
2014). Studies indicate providers are interested in guidelines to help guide practice, but 
no such guidelines exist for genetic counselors (Richter et al., 2013). This particular study 
looks to identify specific areas within VUS reclassification in which genetic counselors 





reclassifications. Results may have wide reaching implications, as the issue of VUS 
reclassification is not unique or limited to cancer genetics only (Plon et al., 2008). 
2.3 Materials and Methods 
   2.3.1 Participants. 
Genetic counselors that are currently offering multiplex cancer genetic testing to their 
patients on an ongoing basis were eligible to participate in this study. We anticipated 
minimal risk for those counselors who participated, as they were responding to questions 
regarding ongoing practices in their working environment.  The following inclusion 
criteria applied to the research conducted: 
• Genetic counselors working in the cancer field and offering multiplex genetic 
testing 
• Cancer genetic counselors practicing in the United States 
• Cancer genetic counselors practicing in Canada who may be members of the 
NSGC 
While the following exclusion criteria applied: 
• Genetic counselors not currently practicing as a cancer genetic counselor  
• Cancer genetic counselors not offering multiplex genetic testing 
   2.3.2 Invitation to Participate. 
Participants were invited to complete the study through the distribution of an online 
questionnaire through the National Society of Genetic Counselors (NSGC) Cancer 
Special Interest Group, as well as via an email blast to all NSGC members. Included in 
the notification was an invitation letter to participate in an online questionnaire regarding 





no participants were obtained via this method of recruitment. The participants remained 
completely anonymous; no identifying information was gathered unless they consented to 
take part in a telephone interview. It is important to note that due to difficulty in re-
contacting participants no phone interviews were conducted. In addition, as a result of 
time constraints a pilot study was not carried out prior to this research study going live. 
   2.3.3 Data Collection. 
The primary method of data collection for this research project was via an online 
questionnaire. The questionnaire was posted on www.surveymonkey.com and could be 
accessed by going to www.surveymonkey.com/s/VUSreclassificaiton. The online 
questionnaire consisted of a series of statements and questions for the participant to 
consider and answer with the final section collecting demographic information. In 
addition to the online survey it was originally proposed that volunteers from the 
participants would be interviewed via telephone in order to allow them to share their 
thoughts and opinions regarding VUS reclassification. Unfortunately, this qualitative 
aspect of the research project was not completed due to a difficulty in re-contacting those 
participants who had indicated that would be willing to be interviewed. The limitations of 
not conducting thorough qualitative analysis in addition to analyzing the quantitative 
results has been recognized and acknowledged. This research study was reviewed and 
approved by the Institutional Review Board, Office of Research Compliance, of the 
University of South Carolina, Columbia, SC, on August, 2014.  
   2.3.4 Data Analysis & Statistical Analysis. 
Descriptive statistical analysis using Microsoft Office Excel software was used to address 





therefore percentages and frequencies could be calculated. For quantitative analysis, 
Statistical Analysis System (SAS) 9.4 was used after data was transferred from Excel 
spreadsheets. Inferential statistical techniques were used to make comparisons and 
explore associations between variables from the survey.  To assess associations between 
two categorical variables, the chi-square test for independence was implemented as well 
as Fisher’s Exact Test.  Grounded theory methods were employed to code free-response 
questions and identify emergent themes.  
2.4 Results 
   2.4.1 Demographic Information. 
An invitation to participate in the online survey was sent in an email blast to the entire 
NSGC membership list, resulting in 216 responses from cancer genetic counselors. Of 
those who responded a total of 176 participants provided demographic information as 
seen in Table 2.1.  
In addition to the demographics represented in Table 2.1, information regarding 
multiplex genetic testing was obtained. Of 215 respondents, 66% order multiplex panels 
at least 50% of the time. Monte Carlo Estimation for Fisher’s Exact Test found that there 
was neither a statistically significant association between ordering multiplex genetic tests 
and the participant’s age, (99% lower conf limit = .7737, 99% upper conf limit = .949, p 
= .7843) nor a statistically significant association between ordering multiplex genetic 
tests and years of work experience, (99% lower conf limit = .0967, 99% upper conf limit 
= .1125, p = .1046). Respondents (n = 176) reported that TAT (48%) and limited clinical 
utility (46%) are the two main reasons as to why they do not order multiplex genetic tests 





reasons such as patient preference, known familial mutation, and specific clinical 
diagnosis. A clear majority (69%) of respondents (n = 215) are not deterred by the variant 
rate when ordering multiplex genetic testing and 70% of respondents (n = 216) indicated 
that variant rate was not a factor that played into their decision making process. Figure 
2.1 illustrates what factors are important and not important to genetic counselors when 
deciding whether single gene or multiplex genetic testing is the best course of action. 
Family history and patient preference are the two most important factors.  
 
Figure 2.1 Contributing factors in respondents’ decision to order single gene tests or 









Table 2.1 Participant Demographics (n = 176) 
                                                                  n                                                          % 
                                                                                     
Age   
20-30 93 53% 
31-40 38 22% 
41-50 19 11% 
51-60 19 11% 
61-70 7 4% 
Gender    
Female 172 98% 
Male 4 2% 
Years experience in the cancer field    
Less than 5 years 109 62% 
5-10 years 30 17% 
10 - 15 years 14 8% 
15 – 20 years 11 6% 
Greater than 20 years 12 7% 
Setting in which they practice    
Academic Institution/University Hospital 61 35% 
Public/Community Hospital 51 29% 
Private Hospital 31 18% 
Private Oncology Group 16 9% 
Genetics Centre 3 2% 
Laboratory 1 1% 
Other (Unspecified hospital, HMO, 
federal group) 
12 7% 
Number of panel tests ordered per 
week    
Less than 5 83 47% 
5-10 16 9% 
10 - 15 74 42% 






   2.4.2 ‘Best practices’ or commonalities employed by genetic counselors when 
dealing with VUS reclassification.  
Almost all (95%) of respondents (n = 183) reported that they felt genetic counselors 
should always be made aware of changes in reclassification. Additionally, of 207 
respondents, 89% either agree or strongly agree that patients should be made aware of 
VUS reclassification regardless of what the reclassification is. Over half (59%) of 
respondents (n = 183) reported that there is not a set protocol in their workplace for re-
contacting patients when a VUS reclassification report is received. A majority (67%) of 
respondents (n = 183) would contact the patient via telephone when a benign 
reclassification is received (Figure 2.2). Upon receiving a deleterious reclassification, 
51% of respondents (n = 183) would notify the patient via telephone while 24% would 
have an in-person appointment, and 19% of respondents selected ‘other’ (Figure 2.3). 
Almost all of those who selected other reported that they would telephone the deleterious 
reclassification information and follow that with an in-person appointment. Of those who 
would not re-contact the patient for a benign reclassification (n = 7), two indicated that 
they would not re-contact the patient for a deleterious reclassification. At the alpha = 0.5 
level of significance, there is a significant association between the reported action of 
genetic counselors for benign reclassification reports and deleterious reclassification 
reports (Monte Carlo Estimate for Fisher Exact Test, 99% Lower Conf Limit =  <.0001, 
99%; Upper Conf Limit = .0005; p = < .0001).  
A free response question looked to determine under what circumstances 
respondents would consider non-disclosure of VUS reclassification results. The majority 





disclosing VUS reclassification information. Many respondents stressed that such 
information was information the patient was entitled to know.  
 “I don't think there are any circumstances when a clinician should 
withhold information about a person's result. Even if a likely benign 
variant is reclassified to a polymorphism, I want to let the patient know, 
even if only for their peace of mind. Plus, it is their result and they have a 
right to know what we are calling it” 
 “None. They deserve "results", whatever they are. I've never thought of "in case 
of death" but will now ask my patient every time.” 
A number of respondents did express that if the reclassification resulted in a downgrade 
or did not change clinical utility nor medical management they would feel more 
comfortable with non-disclosure. Other themes identified were related to patient 







Figure 2.2 Primary means of discussing benign reclassification with the patient. 
 







   2.4.3 Dealing with issues surrounding VUS reclassification in a session. 
Participants were asked a number of questions surrounding how they deal with VUS 
results and VUS reclassification in the genetic counseling session. These questions have 
been shown to be reliable with similar responses for similar groups (Cronbach’s α = .70). 
Nearly all, (99%) of respondents (n = 210) said that they sometimes or always discuss the 
possibility of VUS results prior to consenting the patient for single gene analysis. All 
respondents (n = 210) sometimes or always discussed the possibility of VUS results prior 
to consenting their patients for multiplex genetic testing.  
Eleven respondents indicated that they do not discuss VUS reclassification before 
consenting patients for multiplex genetic testing. Of the subset of people who do not 
discuss VUS reclassification prior to ordering multiplex genetic testing seven respondents 
indicated that they would always discuss the reclassification of variants should a VUS 
result be received. Three respondents indicated they would sometimes discuss variant 
reclassification when a VUS result is received while one respondent indicated that she/he 
would never discuss reclassification. Of the 209 respondents who reported they would 
sometimes or always discuss variant reclassification when a VUS result is received 95% 
will sometimes or always make a plan to communicate the reclassification information. 
Within this plan 53% sometimes or always discuss who is to receive the reclassification 
information in the event of the patient’s death.  
The large majority (97%) of respondents (n = 183) indicated that the protocol for 
re-contacting patients would not be different from what they had used in the past for 





institution were working sufficiently for the handling of VUS reclassifications. For those 
who answered ‘yes’, certain themes emerged. Firstly, a high proportion of respondents 
felt that there are not any issues at this time as the number of VUS reclassification reports 
is manageable. However, multiple participants also stated that with a bigger workload 
and more VUS reclassifications the protocol in place might not stand.  
"They are working sufficiently now, but we do not have a large patient population 
so it has not been as thoroughly tested to find any weaknesses." 
"We have not had a large number of VUS reclassified so this has not become a 
volume issue" 
Additionally, a set of respondents explained how the methods employed at their 
institution are currently satisfactory, whether the methods are secure emails, letters, in 
person appointments or yearly scheduled follow-ups for patients with a VUS result. 
Genetic counselors who were setting their own protocol with regard to the handling of 
VUS reclassifications expressed their satisfaction at being able to alter it as needed. Of 
the respondents who indicated that methods at their institution were not working 
sufficiently the majority stated that they did not have a set protocol in place or had a 
limited number of VUS reclassification experiences. Commonly, the participants 
declared that they are learning as they go, figuring out how to deal with VUS 
reclassification reports as they gain more exposure to them. Barrier in re-contacting 
patients was another theme identified as having a role in why participants felt that current 





“This year we started a variant follow up program which we enter all VUS results 
into we follow up with the patients every 6 months and update the lab with 
changed and vice versa” 
“Many variants are reclassified 10 + years after the patient had testing and it can 
be difficult to get in contact with the patient if they have not provided updated 
contact information through the years" 
When asked to describe the ideal situation with regard to genetic counseling and the 
management of VUS reclassification reports different key themes were identified as 
follows:  
• Some respondents felt their current protocols worked adequately. 
• Other respondents expressed that the availability of a central database to notify 
genetic counselors of reclassifications would be beneficial in reducing the burden 
on them. 
“Database that constantly searches for reclassifications based on input from labs 
across the country and then will alert when a variant is reclassified.” 
•  A number wanted all laboratories to always send VUS reclassification reports 
regardless of whether the VUS was upgraded or downgraded. 
“Genetic counselors shouldn't have to waste their time looking into a VUS every 
year, etc.  They should be able to trust that the lab will notify them if there is an 





• A proportion of respondents felt the responsibility for re-contact should ideally 
fall on the patient. 
“Patients MUST bear the responsibility to re-contact us--we try to find them if 
something needs to be conveyed, but people move/change phone 
numbers/change names so often that it is simply not possible to track everyone 
down.  Sometimes I have trouble getting ahold of a patient we tested a few 
weeks ago to give the initial results; finding them months or years or decades 
after the fact is infinitely more challenging.” 
   2.4.4 The needs and wants of genetic counselors with regard to practice guidelines. 
Over half (62%) of respondents (n = 178) agreed or strongly agreed that there was a need 
for practice guidelines regarding VUS reclassifications. A proportion (30%) neither 
agreed nor disagreed while 8% disagreed and do not think that practice guidelines are 
necessary. Monte Carlo estimate for Fisher’s Exact Test showed no significant 
association between whether the respondents felt that practice guidelines are necessary 
and their workplace (99% Lower Conf Limit = .1103; 99% Upper Conf Limit = .1269; p 
< .1186). There was a significant difference in belief about whether practice guidelines 
should be developed between people who order multiplex genetic tests less than 50% of 
the time and those who order multiplex genetic testing greater than 50% of the time (row 
mean scores differ p < .0111). The Cochran-Mantel-Haenszel Statistic used to calculate 
the row mean scores differ value is able to ignore the fact that twice as many people 
chose ‘order more than 50% multiplex genetic testing’. Thus, those respondents who 
order multiplex genetic testing less than 50% of the time agree more strongly that 





be addressed in practice guidelines were “who is responsible for re-contact of the patient 
following a variant reclassification” and “the laboratories involvement and 
responsibilities”. When asked who should be responsible for monitoring the status of a 
VUS and who should be responsible for re-contacting the patient should a VUS become 
reclassified, 77% of respondents (n = 183) indicated that laboratory personnel should be 
responsible for the monitoring of VUS’s while 77% of respondents (n = 183) also 
indicated that genetic counselors should be responsible for re-contact of the patient if a 
VUS becomes reclassified. Chi-square analysis determined that there was a significant 
association between these two questions (p < .0001).  
A number of free response questions aimed to gain a more in depth understanding 
of respondent’s thoughts and opinions regarding VUS reclassification and practice 
guidelines. Many respondents felt that the issue regarding re-contacting of the patient and 
the barriers associated should be addressed within guidelines. The importance of 
clarifying to what extent genetic counselors must attempt to re-contact patients and what 
steps to take when they cannot re-contact the patient was evident in respondents answers.  
"What the GC's responsibility is in the event the patient cannot be re-contacted - 
what is our due diligence?"  
"The most important item is who is responsible. We had a situation where a 
physician ordered a test and the patient had a VUS (GC was not involved). 
Then the GC saw a new ovarian patient, and it was found that she was the 
sister of the patient with a VUS. The GC discovered that the VUS had been 





switched physicians and this info fell through the cracks. When this was 
discussed with both physicians, they blamed each other and neither would 
take responsibility." 
An additional theme identified was a need for clarification of the role of laboratories in 
VUS reclassification. Many respondents expressed that although laboratories should be 
responsible for monitoring the status of a VUS, not all laboratories report out all 
reclassification results.  
“Needs to be a guideline for all laboratories, since different labs have different 
protocols and this can be confusing for counselor and patients." 
“The front end of the process is most important and needs to be 
standardized. Each lab must have a reliable process for reclassification 
and communication to the clinician who originally ordered the test 
(physician or GC). Once this information is sent to the clinician, how it's 
handled from there should be fairly straightforward and can vary by 
clinic.” 
Finally, some respondents indicated in their free responses that no practice guidelines are 
necessary. These genetic counselors either reasoned that such guidelines would set 
genetic counselors up for liability issues or could not be implemented due to many 
institutions and workplaces functioning uniquely. 






“I think this type of guideline has the potential to set GCs up for great liability 
….. I strongly encourage people to think about legal liabilities this could create 
before setting a precedent and creating a guideline”  
2.5 Discussion 
The goal of this research study was to gain an understanding of the practices and methods 
currently being employed by cancer genetic counselors in their handling of the 
reclassification of VUS results. Additionally, we wanted to explore and assess both the 
needs and wants of genetic counselors with regard to the management of VUS 
reclassifications in the genetic counseling setting. As over half of respondents order 
multiplex genetic testing at least 50% of the time in their clinical practice it was felt that 
this was an appropriate population to survey regarding panel testing and issues that may 
arise in the cancer setting. Additionally, the genetic counselors surveyed are clearly not 
frightened by or scared of possible VUS results and variants do not seem to play an 
important factor in the decision to order multiplex testing over single gene testing.  
Our first aim was to understand whether genetic counselors are employing similar 
practices across the board for the management of VUS reclassifications, despite a lack of 
guidelines. Unexpectedly, we determined that genetic counselors do appear to be 
applying standard procedures when it comes to VUS reclassifications. Common practices 
are being utilized. The majority of genetic counselors surveyed would telephone a patient 
with a benign reclassification while more genetic counselors felt an in-person 
appointment was appropriate for a deleterious reclassification. Similar observations were 





reclassifications that arise due to BRCA testing. In their study population of 410 genetic 
counselors, the majority call the patient and mail benign VUS reclassifications while for 
deleterious reclassifications the majority also met the person face to face (Scherr, Lindor, 
Malo, Couch, & Vadaparampil, 2015).  
Overall, it does appear that common practice is to inform patients of any 
reclassification, regardless of its status, as the large majority of respondents expressed 
how a reclassification result was information the patient was entitled to and had a right to 
know. Cancer genetic counselors appear to have a strong feeling that they are not 
gatekeepers of information and that test results, regardless of their meaning, are the 
patient’s property. 
 Despite genetic counselors employing common practices, the majority of 
respondents indicated that their workplace did not have a set protocol for the handling of 
VUS reclassifications. A number of respondents expressed how they were formulating 
procedures to handle reclassifications as they go. Although this currently seems to be 
sufficient, with a larger workload likely over the course of time it must be considered that 
not having a set protocol could be detrimental. At present the workload is manageable but 
for many the methods they are employing have not yet been rigorously tested as to their 
limits and therefore may prove troublesome in the future. Several respondents expressed 
this same sentiment in open-ended responses. Therefore, genetic counselors must begin 
to think ahead to ensure that in the future their methods will continue to work 





Next, it was important for us to understand the manner in which genetic 
counselors handle VUS reclassifications during the genetic counseling session itself. 
Again, global similarities in practices were observed. In our population, it is standard of 
practice to discuss the possibility of VUS results prior to conducting genetic testing; all 
respondents stated they sometimes or always do this before both single gene and 
multiplex genetic testing. For the purpose of this study we were interested in whether the 
reclassification of VUS results was also included in this discussion as a standard of 
practice. VUS reclassification is something that genetic counselors appear to think about 
and see as an important factor to discuss prior to conducting testing. Only 11 of 210 
respondents do not talk about reclassification of variants before conducting multiplex 
genetic testing. Three of these 11 respondents will only sometimes talk about 
reclassification when a VUS result is received, while one respondent will never talk about 
reclassification upon receiving a VUS result. This study did not specifically assess what 
genetic counselors include in their discussion about VUS reclassification but it was 
determined that 95% of those who talk about reclassification in the genetic counseling 
session make a plan to communicate reclassification information should it become 
available in the future.  It has previously been discussed in the literature that due to the 
average time (typically in years) it takes for a VUS to become reclassified, a discussion 
surrounding who should receive reclassification information in the event of the patient’s 
death should be broached by the genetic counselor (Murray et al., 2011). We did not 
expect the majority of genetic counselors to be doing this; however, approximately half 





Finally, we explored in-depth what areas genetic counselors feel they need 
guidance with or clarification of in terms of VUS reclassification. Furthermore, we 
wanted to investigate whether genetic counselors feel a need for specific practice 
guidelines relating to this topic. Interestingly, it appears that a majority of the genetic 
counselors surveyed feel that they are prepared for VUS reclassification if and when it 
arises, for many it may simply mean an extension of practice that they are already 
familiar with through single gene analysis. Most agreed or strongly agreed that practice 
guidelines regarding VUS reclassification are needed, while a proportion did not have an 
opinion either way. We further analysed the data to determine whether those ordering a 
larger proportion of multiplex genetic tests were either more for or against practice 
guidelines. The proportion of people who disagreed with the statement ‘There is a need 
for practice guidelines regarding VUS reclassification and how the reclassification of 
VUS results should be handled by genetic counselors’ was higher in those who ordered 
multiplex genetic tests more than 50% of the time in their clinical practice and vice versa, 
a higher proportion of those who order multiplex genetic tests less than 50% of the time 
more strongly agreed with the statement. Perhaps, genetic counselors with more 
experience and knowledge regarding multiplex genetic testing and the handling of related 
issues do not see VUS reclassifications as an area within cancer genetics that requires 
specific guidelines. Those with less experience who feel they need clear guidance may 
benefit from further education or management tips on how to handle VUS 
reclassifications rather than guidelines themselves. Some respondents disagreed and felt 





concern for some while others felt that guidelines could not be implemented across all 
institutions. Both of these topics are valid concerns that we had not previously identified. 
  An issue that has been discussed in other literature is the barrier that can arise in 
re-contacting a patient when a VUS is reclassified (Murray et al., 2011). In this study, 
this too was identified as an area of concern for genetic counselors. Precisely, 
respondents recognized that barriers in re-contacting patients may exist and questioned to 
what lengths must the genetic counselor go in order to contact the patient. A critical 
question we identified was when barriers in re-contacting arise, at what point is it no 
longer the responsibility of the genetic counselor to inform the patient of the 
reclassification information? An additional area identified as being of concern to 
respondents was the laboratories involvement and responsibilities. For respondents, this 
was identified as the second most important topic to be included in any guidelines 
relating to VUS reclassification. Genetic counselors felt strongly that the laboratories are 
responsible for the monitoring of variant states; however, many expressed unease due to 
laboratories each having different protocols. The unease and confusion seemed to lie with 
the fact that there are no standards for variant communication across the many 
laboratories performing clinical genetic analysis of cancer genes. It remains to be seen 
whether guidelines for the genetic counseling practice could influence or dictate 
laboratory standardization. 
Study Limitations   
There are several important study limitations to consider. First, a recognized limitation of 





VUS reclassifications in their clinical practice. Importantly, a proportion of respondents 
have never received a VUS reclassification. Thus, it is possible that their responses to 
questions surrounding whether systems in place are working sufficiently or not will 
change in the future upon receiving more VUS reclassifications. Secondly, a potential 
limitation may be that the majority of participants had less than five years experience 
working in the cancer field.  Finally, despite having a total of 216 participants, a number 
of questions, for reasons unknown were skipped by a significant number of respondents 
and henceforth were not as amenable to statistical analysis. This is particularly true for 
the demographics portion of the survey.  
Directions for Future Research 
Future research is needed to delve deeper into the observations made by this preliminary 
study and ensure genetic counselors are well prepared for the reclassification of VUS 
results. As this area is moving at such a breakneck pace, it is plausible to reason that 
should this survey be re-administered in six months time the answers and opinions of 
respondents may have changed. A reasonable ‘next-step’ would be to conduct in-depth 
qualitative analysis through interviewing cancer genetic counselors. Such research would 
allow for the thorough exploration of opinions and thoughts surrounding this topic that 
may not have been expressed nor explored through the online survey employed in this 
study. Specifically, we now know that genetic counselors discuss VUS reclassification 
with their patients so it would therefore be highly beneficial to determine the particular 
details about reclassification that are explained. Furthermore, it would be of interest to 
determine the details of the plan to communicate reclassification that is set up between 





understanding of how genetic counselors and the institutions in which they work keep 
track of their patients who have received VUS results in the past; this study did not assess 
this question. Advancing our knowledge in all these areas would help the genetic 
counseling profession reach a consensus in relation to the genetic counselors’ role and 
responsibilities with regard to VUS reclassification results. 
2.6 Conclusions  
To our knowledge the genetic counseling community has not yet explored in depth the 
genetic counselors role and responsibilities with regard to VUS reclassification. 
Therefore, we believe this study to be of great value to our profession. 
Unexpectedly, this research study revealed that cancer genetic counselors across 
the board are currently employing similar methods in their handling of VUS 
reclassification results. As a whole they feel that reclassification results are important 
information for the patient to be aware of and a topic that is essential in the discussion 
surrounding multiplex cancer genetic testing. Despite this, we feel that cancer genetic 
counselors may not be completely prepared for an increase in the number of 
reclassification results and workload expected in the future. Mauer et al. (2011) have 
previously highlighted a need for providers to be prepared for such an increase in 
workload. Many participants are learning as they go without any set protocol in place for 
when a reclassification result is received.  
Additionally, we propose that this study highlights the need for guidelines or 
recommendations surrounding the role and responsibilities of the genetic counselor with 





majority of our study participants feel that guidelines would be both beneficial and 
useful. However, we are now aware of some important concerns regarding the possible 
implications of guidelines that require further in depth analysis.  
Additional research into VUS reclassification and the role and responsibilities of 
the genetic counselor is warranted. We propose that thorough qualitative analysis which 
fully explores cancer genetic counselors’ opinions, reservations and suggestions relating 
to VUS reclassification be conducted. Given additional studies, perhaps a Working 
Committee of the NSGC Cancer Special Interest Group (Cancer SIG) could be convened 
to consider the totality of information and propose a draft guideline (if needs for a 
guideline are confirmed), requesting input and comments from practicing cancer genetic 
counselors prior to finalization. Subsequent studies that expand on the knowledge gained 
through this research would be hugely beneficial to the genetic counseling community, 













Chapter 3. Conclusions 
To our knowledge the genetic counseling community has not yet explored in depth the 
genetic counselors role and responsibilities with regard to VUS reclassification. 
Therefore, we believe this study to be of great value to our profession 
Unexpectedly, this research study revealed that cancer genetic counselors across 
the board are currently employing similar methods in their handling of VUS 
reclassification results. As a whole they feel that reclassification results are important 
information for the patient to be aware of and a topic that is essential in the discussion 
surrounding multiplex cancer genetic testing. Despite this, we feel that cancer genetic 
counselors may not be completely prepared for an increase in the number of 
reclassification results and workload expected in the future. Mauer et al. (2011) have 
previously highlighted a need for providers to be prepared for such an increase in 
workload. Many participants are learning as they go without any set protocol in place for 
when a reclassification result is received.  
Additionally, we propose that this study highlights the need for guidelines or 
recommendations surrounding the role and responsibilities of the genetic counselor with 
regard to VUS reclassification. Similar to findings that Richter et al. (2013) identified, the 
majority of our study participants feel that guidelines would be both beneficial and 
useful. However, we are now aware of some important concerns regarding the possible 




Additional research into VUS reclassification and the role and responsibilities of 
the genetic counselor is warranted. We propose that thorough qualitative analysis which 
fully explores cancer genetic counselors’ opinions, reservations and suggestions relating 
to VUS reclassification be conducted. Given additional studies, perhaps a Working 
Committee of the NSGC Cancer Special Interest Group (Cancer SIG) could be convened 
to consider the totality of information and propose a draft guideline (if needs for a 
guideline are confirmed), requesting input and comments from practicing cancer genetic 
counselors prior to finalization. Subsequent studies that expand on the knowledge gained 
through this research would be hugely beneficial to the genetic counseling community, 
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Appendix A: Invitation Letter to Potential Participants 
 
Dear Potential Participant: 
You are invited to take part in a graduate research study focusing on variant 
reclassification in cancer genetic counseling.  I am a graduate student in the genetic 
counseling program at the University of South Carolina School of Medicine.  My 
research looks at whether cancer genetic counselors are preparing themselves for the 
work that will come with an increase in the number of variants that become 
reclassified.  The research involves taking a survey that can be found at 
www.surveymonkey.com/s/VUSreclassification. 
The survey proposes a number of questions and asks your opinion on different matters 
relating to multi-gene panel testing and variant reclassification.  If you do not wish to 
answer a certain question, please skip that question and continue with the rest of the 
survey. 
All responses from the surveys will be kept anonymous and confidential.  We only 
ask for your name and phone number in the event that you are interested in providing 
more information at a later date over the phone.   It is not necessary that you provide 
this information. The results of this study might be published or presented at scientific 
meetings; however, your answers will not be identified in any way.  The survey 
should take about 15-20 minutes to complete. 
Your participation in this research is voluntary.  By completing the survey, you are 
consenting that you have read and understand this information.  At any time, you may 
withdraw from the study by not completing the survey. 
Thank you for your time and consideration for taking part in this study.   Your 
answers may help genetic counselors gain much needed guidance and provide the best 
care for their patients with regard to cancer panel testing and variant reclassification.  
If you have any questions about this research, you may contact either me or my 
advisor, Brook White, MS, CGC, at the information below.  If you have any questions 
about your rights as a research member, you may contact the Office of Research 
Compliance at the University of South Carolina at (803)777-7095. 
Sincerely, 
Niamh White, B.A (Mod) in Human Genetics   
Master of Science Candidate 
University of South Carolina School of Medicine     
USC Genetic Counseling Program  
Two Medical Park, Suite 208 






Brook White, MS, CGC 
Genetic Counselor 
Levine Cancer Institute 
1021 Morehead Medical Dr. 





Appendix B: Online Survey 
 
1. What percent of genetic tests that you order are multi-gene tests? 
□ 0%   □ 1-25%   □ 25-50%    □ 50-75%     □ 75-100%  
2. When you do not order multi-gene tests, why not (check all that apply) 
□ Institutional protocol        
□ High rate of variants        
□ Guidelines do not recommend      
□ Expense or Insurance        
□ Limited Clinical Utility        
□ Turn around time  
□ Other (Please explain) 
3. Does the variant rate deter you from ordering next generation sequencing 
and/or panel tests? 
□ Yes       □ No 
Please elaborate  






5. If you order both single gene and multi gene, panel testing, what factors 
contribute to the decision to order one over the other (check all that apply) 
□ Family history        
□ Potential Liability  
□ Insurance coverage        
□ Variant rate 
□ Turn around time        
□ Patient preference 
□ Other   (Please explain)     
6. You discuss the possibility of variants and uncertain tests results in a session 
prior to conducting single gene/single site sequence analysis  
□ Never       □ Sometimes        □ Always      
7. You discuss the possibility of variants and uncertain test results in a session 
prior to conducting next generation sequencing and/or panel testing  
□ Never       □ Sometimes        □ Always      
8. Variant reclassification is discussed in a session prior to conducting next 
generation sequencing and/or panel testing  
□ Never       □ Sometimes        □ Always  
 
9. If a VUS is received, variant reclassification is discussed during result 
disclosure 
□ Never       □ Sometimes        □ Always  
10. In this discussion a plan to communicate reclassification information is 
determined  
□ Never       □ Sometimes        □ Always  
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11. You discuss who is to receive the reclassification information in the event of 
the patients death 
□ Never       □ Sometimes        □ Always  
12. Variant reclassification is information that the patient should be made aware 
of only if the variant has been reclassified as deleterious 
□ Strongly Disagree     □ Disagree             □ Neither Agree nor Disagree           
□ Agree                          □ Strongly Agree 
 
13. Variant reclassification is information that the patient should be made aware 
of regardless of what the reclassification status is 
□ Strongly Disagree     □ Disagree             □ Neither Agree nor Disagree                    
□ Agree                           □ Strongly Agree 
 
14. Under what other circumstances would you consider non-disclosure of variant 
reclassification as appropriate? 
 
15. In your workplace is there a set protocol to re-contact a patient with a variant 
reclassification for a VUS 
□ Yes       □ No 
16. If you order multi-gene panels will the protocol for contacting the patient with 
a VUS be different than what you have used in the past?  Please explain. 
□ Yes       □ No 
17. If you have a protocol for NGS multi-gene panels, is your primary means of 
discussing benign reclassification with the patient 
□ Telephone        
□ Mail      
□ In person appointment      
□ Notify physician        




18. What is your primary means of discussing a deleterious reclassification with 
the patient 
□ Telephone        
□ Mail      
□ In person appointment      
□ Notify physician        
□ Do not re-contact 
□ Other (Please explain) 
 
19. Are the methods employed at your institution working and sufficient? Please 
explain why/why not. 
□ Yes       □ No  
20. Given time and resources what would be the ideal situation with regards to 
genetic counseling and the management of variant reclassification 
 
21. There is a need for official practice guidelines regarding variant 
reclassification and how the reclassification of variants should be handled by 
genetic counselors. 
□ Strongly Disagree     □ Disagree              □ Neither Agree nor Disagree                   
□ Agree               □ Strongly Agree 
22. Part A. With regard to practice guidelines what should be included? Please 
list in order of importance (1 being most important and 6 being least 
important)  
□ what to discuss regarding variant reclassification in the counseling session      
□ who is responsible for re-contact of the patient following a variant 
reclassification      
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□ steps to ensure a reliable tracking system        
□ procedure to be followed dependent on each specific situation (i.e. variant 
reclassified as benign compared to a variant reclassified as deleterious)      
□ the laboratories involvement and responsibilities       
□ what to do if a patient cannot be re-contacted 
Part B. In your opinion what is important for you to be included in practice 
guidelines? 
23. Who should be responsible for actively monitoring the status of a variant and 
its reclassification?  
□ Patient      
□ Primary Care Physician     
□ Referring Physician      
□ Genetic Counselor    
□ Laboratory Personnel  
□ Other (Please explain) 
24. Whose duty should it be to re-contact the patient should a variant become 
reclassified? (Please mark with an X).  
□ Primary Care Physician      
□ Referring Physician      
□ Genetic Counselor    
□ Laboratory Personnel 
□ Other (Please explain)  
25. Genetic counselors should be made aware of changes in reclassification 
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□ Always     □ Only when the reclassification is deleterious     □ Never  
26. What is the greatest barrier that you see arising in terms of re-contact of a 
patient after a variant has been reclassified? 
□ Genetic counseling time and resources      
□ Cannot find the patient    
□ Genetic counselor not being notified of the reclassification 
□ Other (Please explain) 
Please answer the following questions about yourself.  
27. What is your age?  
□ 20-30   □ 31-40     □ 41-50     □ 51-60     □ 61-70 
28. What is your gender?        
 
□ Male       □ Female  
 
29. For how many years have you worked in the cancer field? 
□ less than 5 years        □ 5-10 years    □ 10-15 years     □ 15-20 years                
□ greater than 20 years 
30. Where do you practice (university hospital, private oncology group etc.)  
 
31. Approximately how many gene panel tests do you order in a typical week?  
□ less than 5     □ 5-10     □ 10-15     □ 15-20     
 
